Ticagrelor

Generic Name
Ticagrelor
Brand Names
Brilinta, Brilique
Drug Type
Small Molecule
Chemical Formula
C23H28F2N6O4S
CAS Number
274693-27-5
Unique Ingredient Identifier
GLH0314RVC
Background

Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.

Ticagrelor was granted EMA approval on 3 December 2010.
...

Indication

Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.

Associated Conditions
Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
Associated Therapies
-
Clinical Trials
Related News

TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk

First Posted Date
2024-10-31
Last Posted Date
2024-10-31
Lead Sponsor
National Institute of Cardiovascular Diseases, Pakistan
Target Recruit Count
1727
Registration Number
NCT06667349
Locations
🇵🇰

National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

First Posted Date
2024-09-05
Last Posted Date
2024-09-05
Lead Sponsor
Tianjin Institute of Pharmaceutical Research Co., Ltd
Target Recruit Count
14
Registration Number
NCT06584812
Locations
🇨🇳

Beijing Tiantan Hosptial, Capital Medical University, Beijing, China

A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Rosuvastatin
Drug: Ticagrelor
First Posted Date
2024-08-15
Last Posted Date
2024-10-15
Lead Sponsor
AstraZeneca
Target Recruit Count
28
Registration Number
NCT06554821
Locations
🇩🇪

Research Site, Berlin, Germany

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Phase 4
Not yet recruiting
Conditions
Coronary Artery Disease
Interventions
Drug: Aspirin
Drug: Indobufen
Drug: Ticagrelor
First Posted Date
2024-06-11
Last Posted Date
2024-06-18
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
2846
Registration Number
NCT06451198

A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge

Not Applicable
Recruiting
Conditions
Vertebral Artery Stenosis
Brain Disease
Interventions
Drug: Ticagrelor
First Posted Date
2024-03-08
Last Posted Date
2024-03-08
Lead Sponsor
The Fourth Affiliated Hospital of China Medical University
Target Recruit Count
560
Registration Number
NCT06301776
Locations
🇨🇳

the Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease

Phase 4
Not yet recruiting
Conditions
Coronary Heart Disease
Interventions
Drug: Ticagrelor
Drug: Clopidogrel
Drug: Aspirin
First Posted Date
2023-10-18
Last Posted Date
2023-10-18
Lead Sponsor
Fu Wai Hospital, Beijing, China
Target Recruit Count
292
Registration Number
NCT06088433
Locations
🇨🇳

Fuwai Hospital, Beijing, Beijing, China

Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage

Not Applicable
Recruiting
Conditions
ST Elevation Myocardial Infarction
Interventions
Drug: Ticagrelor
Drug: Aspirin
First Posted Date
2023-08-14
Last Posted Date
2024-08-27
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
200
Registration Number
NCT05986968
Locations
🇳🇱

Noordwest Ziekenhuisgroep Alkmaar, Alkmaar, Netherlands

🇳🇱

Amsterdam UMC, Amsterdam, Netherlands

🇳🇱

Radboudumc, Nijmegen, Netherlands

and more 2 locations

Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI

First Posted Date
2023-06-22
Last Posted Date
2023-06-22
Lead Sponsor
Mina Wageh Mohareb
Target Recruit Count
60
Registration Number
NCT05911659
Locations
🇪🇬

Faculty of medicine of girls, Cardiology department, Al-Azhar University in Cairo, Cairo, Egypt

Ticagrelor vs. Clopidogrel in Post PCI Patients

Not Applicable
Completed
Conditions
Stable Chronic Angina
Interventions
Drug: Clopidogrel
Drug: Ticagrelor
First Posted Date
2023-05-15
Last Posted Date
2023-05-16
Lead Sponsor
Shiraz University of Medical Sciences
Target Recruit Count
476
Registration Number
NCT05858918
Locations
🇮🇷

Professor Kojuri Cardiology Clinic, Shiraz, Iran, Islamic Republic of

Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Prasugrel
Drug: Ticagrelor
First Posted Date
2022-12-08
Last Posted Date
2022-12-08
Lead Sponsor
Germano Di Sciascio
Target Recruit Count
50
Registration Number
NCT05643586
Locations
🇧🇪

Aalst cardiovascular center, Aalst, Belgium

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy